CEBINA announces the launch of DanubeNeuro, an acceleration program transforming insightful neuroscience research into novel therapeutics

CEBINA GmbH, Central European Biotech Incubator and Accelerator, announces today the launch of the DanubeNeuro program advancing breakthrough innovative academic research projects in the field of neurodegeneration, dementia and aging.

Supported by a dedicated group of family office and venture capital investors, the DanubeNeuro acceleration program will identify and develop groundbreaking research projects with potential to deliver innovative drugs, diagnostic methods, disease biomarkers and imaging approaches in the neurodegenerative diseases field.

Investors include Dolby Family Ventures, Hong Kong based Kinled Holding Ltd, and the Swiss Wild (Leica/Wild-Leitz) Family Office.